132 related articles for article (PubMed ID: 8405289)
1. Remote microglial activation in the quinolinic acid model of Huntington's disease.
Töpper R; Gehrmann J; Schwarz M; Block F; Noth J; Kreutzberg GW
Exp Neurol; 1993 Oct; 123(2):271-83. PubMed ID: 8405289
[TBL] [Abstract][Full Text] [Related]
2. Expression of GFAP in the striatum and its projection areas in response to striatal quinolinic acid lesion in rats.
Block F; Schwarz M
Neuroreport; 1994 Nov; 5(17):2237-40. PubMed ID: 7881035
[TBL] [Abstract][Full Text] [Related]
3. Deficits induced by quinolinic acid lesion to the striatum in a position discrimination and reversal task are ameliorated by permanent and temporary lesion to the globus pallidus: a potential novel treatment in a rat model of Huntington's disease.
Joel D; Ayalon L; Tarrasch R; Weiner I
Mov Disord; 2003 Dec; 18(12):1499-507. PubMed ID: 14673887
[TBL] [Abstract][Full Text] [Related]
4. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
[TBL] [Abstract][Full Text] [Related]
5. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
[TBL] [Abstract][Full Text] [Related]
6. Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: evidence that basal ganglia modulate sensory cortical input.
Schwarz M; Block F; Töpper R; Sontag KH; Noth J
Ann Neurol; 1992 Sep; 32(3):358-64. PubMed ID: 1329611
[TBL] [Abstract][Full Text] [Related]
7. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
[TBL] [Abstract][Full Text] [Related]
8. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
Figueredo-Cardenas G; Anderson KD; Chen Q; Veenman CL; Reiner A
Exp Neurol; 1994 Sep; 129(1):37-56. PubMed ID: 7925841
[TBL] [Abstract][Full Text] [Related]
9. Changes in the mitochondrial enzyme activity in striatal projection areas after unilateral excitotoxic striatal lesions: partial restoration by embryonic striatal transplants.
Nakao N; Nakai K; Itakura T
Exp Neurol; 1998 Oct; 153(2):268-76. PubMed ID: 9784286
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
[TBL] [Abstract][Full Text] [Related]
11. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
Ryu JK; Kim SU; McLarnon JG
Exp Neurol; 2004 May; 187(1):150-9. PubMed ID: 15081596
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.
Emerich DF; Winn SR; Hantraye PM; Peschanski M; Chen EY; Chu Y; McDermott P; Baetge EE; Kordower JH
Nature; 1997 Mar; 386(6623):395-9. PubMed ID: 9121555
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Olds ME; Jacques DB; Kopyov O
Synapse; 2005 Jan; 55(1):26-36. PubMed ID: 15499610
[TBL] [Abstract][Full Text] [Related]
14. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
[TBL] [Abstract][Full Text] [Related]
15. Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
Rite I; Machado A; Cano J; Venero JL
Exp Neurol; 2005 Mar; 192(1):142-55. PubMed ID: 15698628
[TBL] [Abstract][Full Text] [Related]
16. Amphetamine-induced Fos expression is evident in gamma-aminobutyric acid neurons in the globus pallidus and entopeduncular nucleus in rats treated with intrastriatal c-fos antisense oligodeoxynucleotides.
Ishida Y; Denovan-Wright E; Hebb MO; Robertson HA
Exp Neurol; 2002 May; 175(1):275-81. PubMed ID: 12009778
[TBL] [Abstract][Full Text] [Related]
17. Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.
Hughes PE; Alexi T; Williams CE; Clark RG; Gluckman PD
Neuroscience; 1999; 92(1):197-209. PubMed ID: 10392842
[TBL] [Abstract][Full Text] [Related]
18. Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression.
Wright AK; Miller C; Williams M; Arbuthnott G
Brain Res; 2008 Jun; 1216():78-86. PubMed ID: 18495090
[TBL] [Abstract][Full Text] [Related]
19. Chronic intrastriatal dialytic administration of quinolinic acid produces selective neural degeneration.
Bazzett TJ; Becker JB; Kaatz KW; Albin RL
Exp Neurol; 1993 Apr; 120(2):177-85. PubMed ID: 8387931
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
Ghorayeb I; Puschban Z; Fernagut PO; Scherfler C; Rouland R; Wenning GK; Tison F
Exp Neurol; 2001 Jan; 167(1):133-47. PubMed ID: 11161601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
